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At present, the mechanism leading to bladder cancer is still poorly understood, and our knowledge about early events in
tumorigenesis is limited. This study describes the changes in gene expression occurring during the neoplastic transition from normal
bladder urothelium to primary Ta tumours. Using DNA microarrays, we identified novel differentially expressed genes in Ta tumours
compared to normal bladder, and genes that were altered in high-grade tumours. Among the mostly changed genes between normal
bladder and Ta tumours, we found genes related to the cytoskeleton (keratin 7 and syndecan 1), and transcription (high mobility
group AT-hook 1). Altered genes in high-grade tumours were related to cell cycle (cyclin-dependent kinase 4) and transcription (jun
d proto-oncogene). Furthermore, we showed the presence of high keratin 7 transcript expression in bladder cancer, and Western
blotting analysis revealed three major molecular isoforms of keratin 7 in the tissues. These could be detected in urine sediments from
bladder tumour patients.
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Bladder cancer is a serious health problem. Neoplastic transforma-
tion of urothelial cells gives rise to urothelial carcinomas, which
has a very high prevalence in Western societies (Edwards et al,
2002). Patients diagnosed with bladder cancer often get recurrent
tumours. Tumour recurrence develops in 35% of patients with
papillary urothelial neoplasm of low malignant potential
(PUNLMP), in 71% of patients with low-grade urothelial
carcinoma, and in 73% of patients with high-grade carcinoma
(Holmang et al, 2001). Ta tumours are superficial papillary
neoplasms that do not invade the submucosa and muscle layers of
the bladder. At present, the mechanism leading to bladder cancer
is still poorly understood, and our knowledge about early changes
occurring during transformation of normal urothelium into
noninvasive Ta tumours is limited. Over recent years, much work
has been carried out to reveal events relevant to understanding the
aetiology of bladder cancer. It has become apparent that urothelial
carcinoma is developing through a multistep process with
increasing accumulation of multiple genetic alterations (reviewed
in Orntoft and Wolf, 1998). Previous studies have shown the
importance of genetic alterations affecting known oncogenes and
tumour suppressor genes (Knowles, 1999). An increase in grade,
characterised by a loss of differentiation, and the presence of
dysplasia as well as tumour multiplicity are determinants of poor
prognosis (Heney, 1992; Prout et al, 1992). Studies using
microsatellites, and more recently, array-based comparative
genomic hybridisation, have shown that loss of heterozygosity
(LOH) especially loss of chromosome 9 is a frequent finding in
early stage bladder cancer (Cairns et al, 1993; Ruppert et al, 1993;
Keen and Knowles, 1994; Primdahl et al, 2002). Many molecular
variables have been suggested to be useful in the classification and
prediction of progression. Among those have been oncogenes (H-
ras), tumour suppressors (p53), cell-cycle proteins, growth factors
and cell adhesion molecules to name a few (Cordon-Cardo et al,
2000; Oxford and Theodorescu, 2003).
DNA microarray analysis has emerged as an important tool
to identify genes that are differentially expressed in normal and
tumour tissues. Previously, we have used this technology to
identify classes of differentially expressed genes by which stage
Ta tumours could be separated from muscle-invasive stage
T2-4 tumours (Thykjaer et al, 2001), and for carcinoma in situ
(Dyrskjot et al, 2004). Furthermore, in a recent study, we identified
unique gene expression profiles for the three major clinical
stages of bladder cancer, Ta, T1 and T2-4 (Dyrskjot et al, 2003).
In the present study, we focus on the neoplastic transition
from normal bladder urothelium to primary Ta tumours.
Using DNA microarrays, we define the early gene expression
changes that occur in urothelial neoplasia. We identify novel
differentially expressed genes in Ta tumours compared to normal
bladder, and genes that are altered in high-grade tumours. Four of
these (KRT7, SDC1, CDK4 and JUND) are further characterised
with respect to location by immunohistochemistry. In addition, we
show that keratin 7 is highly expressed in bladder cancer and is
correlating to the protein level, can be detected in urine sediments,
and has three major molecular isoforms, as determined by
Western blotting.
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Tissue material
Urinary bladder tumour specimens (stage Ta) were obtained after
removal of the necessary amount of tissue for routine pathology
examination. Normal bladder tissue biopsies were obtained from
individuals with no history of bladder tumours. They were removed
by taking a cold cup biopsy, to preserve RNA and to maximise the
amount of normal urothelium. Tissue samples were frozen
immediately after surgery and stored at  801C in a RNA preserving
solution of guanidinium thiocyanate. Samples were evaluated twice
according to WHO/ISUP (Epstein et al, 1998). A training data set
was defined containing 34 samples; 25 primary Ta tumours (10
PUNLMP, five low grade, and 10 high grade) and nine normal
bladder biopsies. The nine normal bladder biopsies were also
included in an evaluation data set 1 (N¼32), which contained
another 23 Ta tumours (11 PUNLMP, two low grade, and 10 high
grade). A third data set (N¼81) was defined, which contained the
previously described normal (9) and Ta (48) samples, as well as 24
additional muscle-invasive T2-4 tumours (evaluation data set 2).
Tissue for immunohistochemistry was formalin-fixed and em-
bedded in paraffin. Informed consent was obtained in all cases, and
protocols were approved by the local scientific ethical committee.
Target preparation
Total RNA was purified from tissue samples using a FastPrep
s
instrument and FastRNA
s Kit-Green tubes (Qbiogene, Irvine,
USA), followed by the RNeasy
s mini kit isolation method (Qiagen,
Venlo, NL). From 10mg of total RNA double-stranded cDNA was
prepared using the SuperScript Choice System (Invitrogen,
Carlsbad, USA), according to the manufacturer’s instructions,
except that we used an oligo-dT primer containing a T7 RNA
polymerase promoter site (DNA Technology A/S, Aarhus, DK), as
described by Affymetrix. Labelled cRNA was prepared using the
BioArray High Yield RNA Transcript Labeling kit (Enzo Biochem,
Farmingdale, USA). Biotin-labelled CTP and UTP (Enzo Biochem,
Farmingdale, USA) were used in the reaction, together with
unlabelled nucleotide triphosphates. Unincorporated nucleotides
were removed from the in vitro transcript using the RNeasy
s mini
kit isolation method (Qiagen, Venlo, NL).
DNA microarray hybridisation, washing, and scanning
We fragmented 15mgo fc R N Aa t9 4 1C for 35min in a fragmentation
buffer containing 40mM Tris-acetate (pH 8.1), 100mM potassium
acetate and 30mM magnesium acetate. Prior to hybridisation, the
labelled cRNA mixed with hybridisation buffer (0.1M MES, 1 M NaCl,
20mM EDTA, 0.01% Tween-20) was preheated in 5min to 991Ca n d
then cooled to 451C for 5min before loading onto the Affymetrix
microarray (HG-U133A). We then incubated the probe array for
16h at 451C at constant rotation (60r.p.m.). The washing and
staining procedure was performed in the Affymetrix Fluidics Station.
We exposed each microarray to 10 washing cycles using non-
stringent wash buffer (6  SSPE, 0.01% Tween-20) at 251C followed
by four rounds of wash in stringent wash buffer (100mM MES, 0.1 M
NaCl, 0.01% Tween-20 at 501C. Signal intensities were increased by
antibody amplification. First the microarray was stained in SAPE
stain solution (1  MES buffer, 2mgml
 1 BSA, 10mgml
 1
Streptividin-Phycoerythin (SAPE)), washed in nonstringent wash
buffer, stained in antibody solution (1  MES, 1 M NaCl, 0.05%
Tween-20, 2mgml
 1 acetylated BSA, 100mgml
 1 normal goat IgG,
3mgml
 1 biotinylated antibody), stained with SAPE stain solution
again, and finally washed in nonstringent wash buffer. Microarrays
were then scanned at 560nm using a confocal laser-scanning
microscope with an argon ion laser as the excitation source
(GeneArray Scanner G2500A; Hewlett Packard, Palo Alto, USA).
DNA microarray data analysis
Microarray data were normalised and probe expression measures
calculated using the robust multiarray analysis normalisation
method (Bolstad et al, 2003) implemented in the ArrayAssist 3.0
software package (Stratagene, La Jolla, USA). Nonvarying genes
were eliminated by filtering out genes with variation less than 8000
across the microarrays used. Student’s t-test was applied for
comparisons between independent groups, that is training data set,
(a) primary Ta tumours vs normal bladder biopsies and (b)
primary Ta high-grade tumours vs primary Ta PUNLMP/low
grade; evaluation data set 1, (a) Ta tumours vs normal bladder
biopsies; and evaluation data set 2, normal bladder biopsies vs Ta
and T2-4 tumours. P-values were adjusted for multiplicity using
the Benjamini–Hochberg correction procedure (Benjamini and
Hochberg, 1995). We defined as candidate informative genes those
with unadjusted Po0.05, and as differentially expressed genes
those with a significant expression difference (adjusted for
multiplicity Po0.05).
Identification of over-represented gene categories
Genes can be placed in functional categories, and it is then possible
to test if altered genes are primarily belonging to certain functional
groups. Over-represented gene categories were identified using
EASE software (Hosack et al, 2003). For both the candidate
informative genes (comparing Ta high-grade and PUNLMP/low-
grade tumours) and the differentially expressed genes (comparing
normal and Ta tumours), we determined the major biological
themes. All significant (Po0.05) gene categories were determined
by EASE score, corrected for multiplicity with the global false-
discovery rate function using 1000 iteration trials.
Cluster analysis
Unsupervised hierarchical cluster analysis was performed using
Cluster software. For visualisation we used TreeView software
(Eisen et al, 1998). Nonvarying probesets were eliminated from the
training data set by filtering away probesets with standard
deviation less than 0.5, and expression levels less than 6.5 in at
least four microarrays (log2-transformed data). The filtering
process gave 4144 varying probesets. Microarrays were median-
centred, normalised to the magnitude of 1, and clustered using
average linkage clustering with a modified Pearson correlation as
similarity metric.
Immunohistochemistry
Paraffin-embedded tissue sections were deparaffinised, rehydrated,
boiled in a microwave oven for 5min, allowed to cool at room
temperature for 20min, and then incubated in methanol/H2O2
(100ml methanolþ1.5mlwv
 1 H2O2) for 10min to block
endogenous peroxidase. The tissue sections were then incubated
in TEG buffer (Tris-EGTA, pH 9.0) boiled for 10min in a
microwave, allowed to cool at room temperature for 20min,
incubated with Pronase (DakoCytomation A/S, Glostrup, DK) for
20min at room temperature. Then tissue sections were incubated
with specific antibodies against KRT7(sc-23876) (1:1200),
SDC1(sc-12765) (1:100), CDK4(sc-749) (1:50) and JUND(sc-74)
(1:50) all purchased from Santa Cruz Biotechnology. The primary
antibodies were visualised with the Envisiont visualisation system
and the chromogen DABþ from DakoCytomation A/S (K3868),
followed by counterstaining with Mayer’s haematoxylin and
mounting in Aquatex
s (1.08562; Merck, Darmstadt, Germany).
Immunohistochemical (IHC) evaluation was carried out by two
independent investigators (LD and MA), who scored the cellular
localisation of protein expression. In case of disagreement a
consensus evaluation score was achieved.
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Fresh protein extractions were prepared using RIPA lysisbuffer
(50mM Tris pH 7.5, 150mM NaCl, 1% NP-40, 0.5% deoxycholic
acid) with protease inhibitors added (Complete protease Inhibitor
Cocktail Tablet, Roche, Basel, CH). Approx. 15mg frozen tissue
was mixed with ice cold lysisbuffer (100ml per 5mg tissue) using
the FastPrep instrument (Qbiogene, Irvine, USA) for 2  20s to
release the total proteins. Contaminating urea and salt was
removed from urine and urine pellet samples by o/n dialysis
against dH2O( 4 1C) using Spectra/Por membrane (Spectrum
Chromatography, Houston, USA). Samples were freeze-dried and
lysisbuffer was added. Lysates were mixed thoroughly and
incubated on ice for 30min and followed by centrifugation
(13000g for 10min at 41C). Protein concentrations were
determined by Bradford protein assay (Bio-Rad, Hercules, USA).
SDS–PAGE was performed under reducing conditions at 200V for
50min (10mg total protein per lane). Proteins were transferred to a
methanol activated PVDF membrane (Millipore, Billerica, USA) by
blotting at 30V for 2h. Before incubating with antibody, the
membrane was blocked in blocking buffer (1  phosphate-
buffered saline (PBS), 0.1% Tween-20, 5% skim milk) for 30min
at RT. We then incubated with anti-KRT7 antibody (1:2000) (sc-
23876; Santa Cruz Biotechnology, Santa Cruz, USA) for 1h at RT,
washed three times in washing buffer (1  PBS, 0.1% Tween-20),
and incubated with goat anti-mouse HRP (1:5000) (P0447;
DakoCytomation A/S, Glostrup, DK) secondary antibody for 1h
at RT. The immunoreactive complex was visualised by the ECL
chemiluminescent substrate (GE healthcare, Chalfont St Giles, UK)
and detected by STORM imaging system (GE healthcare, Chalfont
St Giles, UK). For quantification, we used the ImageQuant 5.0
software (GE healthcare, Chalfont St Giles, UK).
Statistics
The w
2 test was used to assess the relation between tumour grade
and clustering pattern. Differences in median recurrence time
between the PUNLMP and high-grade subcluster groups were
assessed using Kaplan–Meier survival analysis, the statistical
significance was assessed by the log-rank test for equality of
survivor functions. The analysis was based on all follow-up
information recorded until March 1, 2004. Values of Po0.05 were
considered statistically significant. Intercooled Stata 8 software
(StataCorp LP, College Station, USA) was used throughout.
RESULTS
Genes differentially expressed between normal bladder
and primary Ta tumours
In order to identify gene expression changes of relevance for early
bladder transformation, the transcriptional profiles of 25 primary
Ta tumours from bladder cancer patients were compared with
those of nine normal bladder biopsies from patients with
no bladder cancer history. Total RNA was extracted from tissue
biopsies, and DNA microarrays (Affymetrix HG-U133A) com-
prised of more than 22000 probe sets were used to analyse
gene expression profiles. Nonvarying genes were eliminated by
filtering out genes with low variance. A panel of 230 differentially
expressed genes (Po0.00005) out of 2416 varying genes distin-
guished the Ta tumours from normal biopsies (Supplementary
Table 1). Of those, 228 (99.1%) were upregulated in Ta tumour
relative to normal biopsies and only two were downregulated.
Table 1 shows the most significant genes identified, some of which
have already been linked to neoplasia. Genes related to cytoske-
leton were keratin 7 (KRT7), keratin 8 (KRT8), junction
plakoglobin (JUP), and syndecan 1 (SDC1); to transcription,
high mobility group AT-hook 1 (HMGA1); to protein folding, fatty
acid binding protein 6, ileal (gastrotropin) (FABP6) and G-rich
RNA sequence binding factor 1 (GRSF1); and to transferase
activity, CD24 antigen (small-cell lung carcinoma cluster 4
antigen) (CD24) and lamin A/C (LMNA). For validation, we
repeated the comparison in a set of 23 independent Ta tumour
Table 1 Differentially expressed genes in Ta tumours compared to normal bladder
Gene transcript
Gene
symbol
a Tentative gene function Probeset ID P-value FC
b
Keratin 7 KRT7 Cytoskeleton organisation 209016_s_at 7.51E-11
c 19.8
IMP (inosine monophosphate) dehydrogenase 2 IMPDH2 RNA binding, spliceosome complex 201892_s_at 4.71E-09
c 2.8
OGT(O-Glc-NAc transferase)-interacting protein
106kDa
OIP106 DNA binding, G -protein coupled receptor
protein signalling pathway
214924_s_at 7.45E-09
c 3.9
Junction plakoglobin JUP Cytoskeleton, cell adhesion 201015_s_at 8.31E-09
c 2.8
Keratin 8 KRT8 Cytoskeleton, protein-nucleus import 209008_x_at 9.21E-09
c 5.4
Protein tyrosine phosphatase, receptor type, F PTPRF Transmembrane receptor protein tyrosine
phosphatase signalling pathway
200635_s_at 1.07E-08
c 2.9
Syndecan 1 SDC1 Cytoskeletal protein binding, integral to plasma
membrane
201286_at 1.51E-08
c 3.8
High mobility group AT-hook 1 HMGA1 Transcription factor 206074_s_at 3.48E-08
c 2.2
Protein phosphatase1, regulatory (inhibitor)
subunit 14B
PPP1R14B Phosphoprotein inhibitor 212680_x_at 4.98E-08
c 2.5
Agrin AGRN Function unknown 212285_s_at 5.18E-08
c 2.1
Fatty acid binding protein 6, ileal (gastrotropin) FABP6 Heat shock protein activity, protein folding 210445_at 6.90E-08
c 3.5
Slingshot 3 SSH-3 Acid phosphatase activity 219241_x_at 7.99E-08
c 2.0
EST Function unknown 216379_x_at 9.99E-08
c 3.1
Syndecan 1 SDC1 Cytoskeletal protein binding, integral to plasma
membrane
201287_s_at 1.16E-07
c 4.3
Hypoxia-inducible factor prolyl 4-hydroxylase PH-4 Oxidoreductase activity 222125_s_at 1.33E-07
c 2.0
G-rich RNA sequence binding factor 1 GRSF1 Isomerase activity, protein folding 201520_s_at 1.51E-07
c 3.6
CD24 antigen (small-cell lung carcinoma cluster 4
antigen)
CD24 Cytoplasm, transferase activity 209771_x_at 1.67E-07
c 3.1
Lamin A/C LMNA Protein kinase C activation, transferase activity 203411_s_at 1.82E-07
c 2.2
FAT tumour suppressor homolog 1 (Drosophila) FAT Negative regulation of cell cycle 201579_at 1.94E-07
c 3.2
Aminoacylase 1 ACY1 Metallopeptidase activity 202740_at 2.11E-07
c 2.4
aProtein localisation measured by IHC shown in bold.
bFold change (median Ta/median N).
cAdjusted for multiplicity Po0.05.
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KRT7 (adjusted for multiplicity Po0.05) and SDC1 (adjusted for
multiplicity Po0.05) in this data set (evaluation data set 1). In
total, we were able to validate 228 of 230 genes this way. The two
genes that were not validated are marked with an asterisk in
Supplementary Table 1.
Altered gene expression in tumours with high-grade atypia
Cancer cells from high-grade tumours contain distinct character-
istics as they in contrast to low-grade tumours frequently display
abnormal cell size, shape, and large hyperchromatic nuclei, and
are associated with a poorer outcome. To identify gene expression
changes related to the high-grade phenotype, we made a
comparative analysis between primary Ta high-grade tumours
and Ta PUNLMP and low-grade tumours (N¼25). Nonvarying
genes were eliminated as previously described. We obtained a
panel of 86 candidate informative genes (Po0.005) out of
2316 varying genes that distinguished high-grade tumours from
PUNLMP/low-grade tumours (Supplementary Table 2). Similar
to previous findings, we also in this case found most genes
upregulated (87.2%) in high-grade tumours compared to
PUNLMP/low-grade tumours. The genes that contributes to
the molecular signature of high-grade tumours are, not
unexpected, related to regulation of the cell cycle, cyclin-dependent
kinase 4 (cdk4); regulation of cell growth, hypothetical protein
MAC30 (MAC30); and transcription, interleukin enhancer binding
factor 2, 45kDa (ILF2), formin binding protein 3 (FNBP3), and jun
D proto-oncogene (JUND) (Table 2). The changes in gene
expression of individual genes were lower when looking at specific
grades in Ta tumours compared to normal biopsies. This could
reflect a biological phenomenon and makes it more difficult to find
highly significantly changing genes when comparing grades, unless
using very large samples sets. The candidates selected seemed
relevant based on their purported function.
Hierarchical clustering of primary Ta tumours
Unsupervised cluster analysis was performed using the 25 primary
Ta tumours to study the possible relationship between gene
expression patterns and cellular atypia grading. The clustering
identified two groups of Ta tumours, which clearly differed in
grades of atypia (Figure 1). One subcluster contained primarily
PUNLMP tumours (denoted PUNLMP subcluster), and the second
had a high content of high-grade tumours (denoted high-grade
subcluster). The distribution of PUNLMP and high-grade tumours
was significant using w
2 test (P¼0.009). Low-grade tumours were
found primarily to cluster with the high-grade tumours. We
estimated the median time to recurrence using Kaplan–Meier
survival statistics. The median time to recurrence of high-grade
subcluster tumours was, as expected, decreased compared to
PUNLMP subcluster tumours; 7 months and 63 months, respec-
tively (P¼0.006) (Figure 2). However, the low-grade tumours
seemed to have the same recurrence pattern as the high grade or
PUNLMP tumours that they clustered together with.
Identification of over-represented gene categories
Identification of over-represented gene categories in gene lists is a
powerful tool to identify possible biological themes involved. We
applied the EASE software (Hosack et al, 2003) to search for over-
represented gene categories in the two lists of genes identified as
showing an altered expressed between primary Ta tumours and
normal biopsies (230 genes), and between primary Ta high-grade
Table 2 Informative genes that distinguish high grade Ta tumours from PUNLMP/low grade Ta tumours
Gene transcript
Gene
symbol
a Tentative gene function Probeset ID P-value FC
b
Hypothetical protein FLJ13725 FLJ13725 Function unknown 45749_at 3.87E-05
c 0.7
Cyclin-dependent kinase 4 CDK4 Regulation of cell cycle 202246_s_at 4.56E-05
c 1.4
Ras homologue gene family, member Q ARHQ GTP binding, Rho small monomeric GTPase
activity
212119_at 9.17E-05
c 1.7
Diazepam binding inhibitor (GABA receptor
modulator, acyl-Coenzyme A binding protein)
DBI Benzodiazepine receptor binding 202428_x_at 1.20E-04
c 1.9
Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta
polypeptide
YWHAZ Protein domain specific binding 200640_at 1.39E-04
c 1.6
H2A histone family, member Z H2AFZ DNA binding, nucleosome assembly, nucleus 213911_s_at 2.02E-04
c 2.4
Diazepam binding inhibitor (GABA receptor
modulator, acyl-coenzyme A binding protein)
DBI Benzodiazepine receptor binding 211070_x_at 2.42E-04
c 2.0
Voltage-dependent anion channel 3 VDAC3 Voltage-dependent anion channel porin activity 208845_at 2.46E-04
c 1.4
Hypothetical protein MAC30 MAC30 Regulation of cell growth 212282_at 4.50E-04
c 3.1
Interleukin enhancer binding factor 2, 45kDa ILF2 RNA polymerase II transcription factor activity,
nucleus
200052_s_at 4.51E-04
c 1.8
Likely ortholog of mouse immediate early
response, erythropoietin 4
LEREPO4 Nucleic acid binding 201593_s_at 5.11E-04
c 1.7
Hypothetical protein MAC30 MAC30 Regulation of cell growth 212281_s_at 5.92E-04
c 3.6
Proteasome (prosome, macropain) subunit, beta
type, 7
PSMB7 Endopeptidase activity, ubiquitin-dependent
protein catabolism
200786_at 6.85E-04
c 1.7
Transgelin 2 TAGLN2 Muscle development 200916_at 7.64E-04
c 1.6
Proteasome (prosome, macropain) subunit, alpha
type, 6
PSMA6 RNA binding, endopeptidase activity, ubiquitin-
dependent protein catabolism
208805_at 8.10E-04
c 1.4
Aldo-keto reductase family 1, member A1
(aldehyde reductase)
AKR1A1 Oxidoreductase activity 201900_s_at 8.22E-04
c 1.3
Peroxiredoxin 1 PRDX1 Cell proliferation, peroxidase activity 208680_at 8.23E-04
c 1.5
Chromosome 13 open reading frame 12 C13orf12 Function unknown 217769_s_at 8.42E-04
c 1.4
Jun D proto-oncogene JUND Regulation of transcription from Pol II promoter,
transcription factor activity
203752_s_at 8.57E-04
c 1.8
Formin binding protein 3 FNBP3 mRNA splicing, signal transduction 213729_at 8.78E-04
c 1.9
aProtein localisation measured by IHC shown in bold.
bFold change (median high grade/median PUNLMP/low grade).
cAdjusted for multiplicity P40.05.
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EASE performs a comparative analysis between gene categories
represented by single gene lists, and gene categories represented by
all genes found on the microarray. The Affymetrix HG-U133A
microarray contains 10937 genes annotated within the biological
process branch of the Gene Ontology (GO) (Ashburner et al, 2000).
Approximately 73% (168 genes) of the genes found differentially
expressed in Ta tumours compared to normal bladder biopsies
were annotated. Several over-represented gene categories were
identified, mostly related to an increased energy turn over, for
example, protein folding, mRNA splicing, energy pathways, glucose
catabolism, lipid metabolism (Table 3). The analysis was repeated
for the panel of 86 candidate informative genes that distinguished
high-grade tumours from PUNLMP/low-grade tumours. In this
case, 67 out of 86 genes were annotated. The over-represented gene
categories were related to RNA/DNA metabolism and proliferation
such as RNA processing, RNA metabolism, protein-nucleus import,
and regulation of cell cycle (Table 3).
Immunohistochemistry
We used IHC staining to verify that the mRNA was being
translated into protein, and to document the cellular localisation
of the proteins. The proteins encoded by a subset of four genes
were analysed. They were selected to represent highly significantly
changed genes, more moderately changed candidate genes, and
based on the availability of commercial antibodies. Two had an
expected localisation within the cytoplasma (KRT7) or the nucleus
(CDK4), and two with no reports on protein localisation in
urothelium (SDC1 and JUND). We have included the results from
the complete evaluation in Supplementary Table 3. In concordance
with previously reports (Glass and Fuchs, 1988), KRT7 was
completely absent in stroma cells, but cytoplasmic expressed in
most normal urothelial (85%) and all cancer cells (100%). We did
not observe any nucleic stainings for KRT7. In agreement with the
gene expression profile of CDK4, its cytoplasmic staining was
increasing from 20% in normal urothelial cells to 100% of cancer
cells. The nucleic CDK4 staining was also increasing from 5% in
normal urothelial cells to 50% in cancer cells (Figure 3). The cell
surface proteoglycan protein SDC1 link the cytoskeleton to the
interstitial matrix (Bernfield et al, 1999). SDC1 displayed a spotted
cytoplasmic staining pattern in cancer cells often with an
accentuation close to the nucleus. We observed an increase in
cytoplasmic SDC1 staining in cancer cells (100%) compared to
normal urothelial cells (65%). Previously, reports has described
SDC1 protein expression linked to the cell membrane, and loss of
membrane staining has been reported to correlate with poor
prognosis (Harada et al, 2003). The observed increase of JUND
gene expression in tumours was accompanied by increased protein
expression. JUND protein expression was increased in cancer cells
compared to normal urothelial cells. The percentage of stained
nuclei increased from 55 to 90%, and the cytoplasmic stain
increase from 65 to 100% in cancer cells.
Keratin 7 expression in bladder cancer
From the gene expression analysis we found the KRT7 transcript
increased by 19.8-fold in primary Ta tumours compared to normal
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Figure 1 Unsupervised hierarchical cluster analysis of 25 Ta tumours
using 4144 genes. Tumour recurrences are represented by black dots. (a)
Time to recurrence in months, and (b) follow-up time in months.
Abbreviations: Ta PUNLMP (Ta P; coloured light grey), Ta low-grade (Ta L;
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Figure 2 Kaplan–Meier survival analysis of the median time to
recurrence in the PUNLMP subcluster and the high-grade subcluster.
Table 3 Identification of over-represented gene categories
Gene category
a EASE score
Analysis of 230 differentially expressed genes in Ta tumours compared to normal
bladder
Protein folding 3.28E-04
Alcohol metabolism 2.44E-03
mRNA splicing 2.58E-03
Energy derivation by oxidation of organic compounds 3.75E-03
Energy pathways 4.19E-03
RNA splicing 6.15E-03
Glucose catabolism 8.59E-03
Obsolete biological process 8.66E-03
Main pathways of carbohydrate metabolism 8.71E-03
Lipid metabolism 8.73E-03
Hexose catabolism 1.32E-02
Alcohol catabolism 1.32E-02
Monosaccharide catabolism 1.32E-02
Catecholamine metabolism 1.62E-02
Analysis of 86 candidate informative genes expressed in high-grade Ta tumours
compared to PUNLMP/low-grade tumours
RNA processing 1.46E-03
RNA metabolism 2.29E-03
RNA modification 3.54E-03
Protein-nucleus import\docking 4.60E-03
Nucleoside monophosphate metabolism 5.16E-03
Nucleoside monophosphate biosynthesis 5.16E-03
Protein-nucleus import 5.89E-03
DNA metabolism 1.22E-02
Nucleocytoplasmic transport 2.07E-02
Regulation of cell cycle 2.79E-02
aAnnotated within GO biological process.
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sbladder biopsies (Table 1). In order to evaluate the diagnostic
value of KRT7 in bladder cancer, we looked at KRT7 expression in
an expanded data set (evaluation data set 2) containing also
muscle-invasive T2-4 tumours. Again, we found strong KRT7
transcript upregulation in Ta tumours (N¼48), as well as in T2-4
tumours (N¼24) compared to normal bladder biopsies (Figure 4).
The median KRT7 expression in normal bladder biopsies was
estimated to be 140.07189.5, and in the cases of Ta and T2-4
tumours, 2775.171165.4 and 1192.77698.7, respectively. This
gives fold changes equal to 19.8-fold (Po0.05) and 8.5-fold
(Po0.05), respectively.
By Western blotting analysis we found that the KRT7 protein
level indeed was increased in Ta tumours (N¼7) (Figure 5). In
addition, the KRT7 protein level in most T2-4 tumours (N¼6) was
also increased, compared to normal biopsies (N¼8). Surprisingly,
several presumably cancer-specific KRT7 isoforms were observed.
At least three major isoforms having different molecular weight
were observed; isoform a (with MW equal to wild type
KRT7¼52kDa), isoform b (B45kDa), and isoform c
(B42kDa). We were able to detect the isoforms b and c in cancer
tissue, but not in normal biopsies. We further extended the
analysis to include KRT7 immunohistochemistry of normal
bladder, Ta and T2-4 tumours (Figure 6A–C). In good agreement
with previous reports (Jiang et al, 2001; Park et al, 2002), we found
that KRT7 expression was highly epithelial cell specific, as the
protein exclusively is expressed in either normal urothelial cells or
cancer cells derived from urothelial cells.
To investigate whether KRT7 mRNA levels correlate with the
protein levels, we simultaneously measured KRT7 gene expression
(by microarrays) and protein expression (by Western blotting) of
four Ta tumours. In all four cases, we found a correlation between
KRT7 protein and mRNA expression (Figure 6D).
As, Ta tumours showed a high KRT7 expression we examined the
potential of KRT7 as a new urine marker for early bladder cancer.
We evaluated the KRT7 protein expression simultaneously in
tumour tissue, plasma, urine supernatant, and urine pellet from
four individuals diagnosed with Ta tumours (Figure 6D). By Western
blotting analysis we were not able to detect KRT7 protein in neither
plasma nor urine supernatant. As expected, we did not detect KRT7
protein in a preparation of leucocytes (negative control). However,
we were able to detect KRT7 protein in urine pellets of some bladder
cancer patients. The sensitivity of Western blotting was low, as only
three out eight individuals were positive for KRT7 protein (not
shown), but may be increased by using ELISA techniques.
DISCUSSION
We have used DNA microarrays to study the gene expression
in primary noninvasive bladder tumours of stage Ta. The purpose
was to define classes of genes that alter in the early malignant
transformation from normal bladder through primary Ta tumours
of atypia grade PUNLMP, low-grade and high-grade. We identified
a number of genes that show an altered expression in the
early steps from normal bladder to Ta tumours. The latter
characterised by a slight increase in number of cell layers, but
otherwise very few cellular abnormalities, compared to normal
Figure 3 Representative immunohistochemical stains for (A, B) KRT7,
(C, D) SDC1, (E, F) CDK4 and (G, H) JUND in Ta tumours in normal
urothelium (left panel) and Ta tumour (right panel). No ab control (I).
Original magnification:  20.
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Figure 4 Expression of KRT7 transcript in normal bladder biopsies, Ta,
and T2-4 tumours (N¼81) measured by microarray analysis. Median
expression levels for each group are represented by horizontal lines.
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Figure 5 Expression of KRT7 protein in normal bladder biopsies, Ta, and
T2-4 tumours analysed by Western blotting. Detection of three KRT7
protein isoforms; (a) isoform a¼wild-type KRT7 (52kDa), (b) isoform b
(B45kDa), and (c) isoform c (B42kDa).
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scells. This early neoplastic process was accompanied by changes in
expression of genes related to functional important classes, such as
cytoskeleton (KRT7, KRT8, JUP, SDC1), protein folding (FABP6,
GRSF1), transferase activity (CD24, LMNA), and transcription
(HMGA1). The tissue composition between normal bladder wall
and papillary tumours vary with respect to cellular content.
However, previous studies have shown that the stromal cells are
not very active in transcription leading to a low RNA level in those
cells (Thykjaer et al, 2001), and the cold cup biopsies are
superficial leading to an enrichment for urothelial cells. Further,
our approach here is to define candidate genes that show a
differential expression between normal mucosa and papillary
tumours, and to confirm the level and location of the encoded
protein, of some of those, by immunohistochemistry. In the part of
the manuscript dealing with differences between various grades of
atypia, the tissue composition is the same in the different groups.
In the present study we have identified several transcripts, which
were previously shown to be overexpressed in cancer. Of particular
interest is the SDC1 gene (Barbareschi et al, 2003; Mor et al, 2003),
which in breast cancer is expressed at high levels, and is related to
an aggressive phenotype, and poor clinical behavior (Barbareschi
et al, 2003). The SDC1 transcript encodes a transmembrane
heparan sulfate proteoglycan, which acts as a receptor of the
extracellular matrix and thereby is involved in cell–cell adhesion,
organisation of cell–matrix adhesion, and regulation of growth
factor signalling. SDC1 is usually located to the cell membrane, and
our finding of a cytoplasmic staning pattern in Ta tumours
suggests a failure in intracellular trafficking, and could indicate
loss of a functional SDC1 protein. This has in some tumours been
related to a poor outcome due to reduced cell adhesion that
promotes metastasis (Harada et al, 2003).
We identified a number of candidate informative genes that alter
expression in high-grade tumours compared to PUNLMP/low-
grade tumours. Of those, one of the most prominent was the CDK4
transcript. The CDK4 gene encodes a Ser/Thr protein kinase, which
phophorylates retinoblastoma (Rb) and is an important cell cycle
regulator (Ortega et al, 2002). In urinary bladder cancer, the
chromosomal region housing CDK4 was found amplified, and
chromosomal amplification has been documented to correlate with
reduced survival and to be consistent with increased tumour grade,
and genetic instability (Simon et al, 2002). In agreement with the
gene expression profile, we found an increased protein expression
of CDK4 in cancer cells from bladder tumours. We also found the
gene expression of JUND altered in high-grade tumours. The
protein encoded by the JUND gene is a member of the AP-1 family
of transcription factors, which mediate the regulation of gene
expression in response to extracellular signalling. The protein is a
functional component of the AP-1 complex, and is strongly induced
by UV-irradiation and may be involved in ML-1 cell apoptosis (Li
et al, 2002). CDK4 and JUND are examples of genes, where both the
gene expression and protein expression is consistently increased in
tumours compared to normal urothelium.
Of the genes distinguishing Ta tumours from normal bladder
biopsies, most were found upregulated. Similarly, we found most of
the genes altered in high-grade tumours to be upregulated. This
finding suggests that both neoplastic transformation of the urothelial
cell layer, and also an increase in cellular atypia is connected with a
massive transcription initiation event. Next, we searched for over-
represented gene categories annotated within the biological process
branch by the Gene Ontology Consortium (Ashburner et al, 2000).
We found several over-represented gene categories within the list of
differentially expressed genes in Ta tumours compared to normal
KRT7 mRNA
expression
40 kDa
Patient 1250-1 Patient  1376-1
T
u
m
o
u
r
P
l
a
s
m
a
U
r
i
n
e
 
s
u
p
.
U
r
i
n
e
 
p
e
l
l
e
t
T
u
m
o
u
r
P
l
a
s
m
a
U
r
i
n
e
 
s
u
p
.
U
r
i
n
e
 
p
e
l
l
e
t
N
e
g
.
 
c
o
n
t
r
o
l
100 89
T
u
m
o
u
r
P
l
a
s
m
a
U
r
i
n
e
 
s
u
p
.
U
r
i
n
e
 
p
e
l
l
e
t
T
u
m
o
u
r
P
l
a
s
m
a
U
r
i
n
e
 
s
u
p
.
U
r
i
n
e
 
p
e
l
l
e
t
N
e
g
.
 
c
o
n
t
r
o
l
Patient 956-2 Patient  1182-1
5 6 KRT7 mRNA
expression
40 kDa
A
B
C
D
Figure 6 Immunohistochemical staining of KRT7 in (A) normal bladder, (B) Ta, and (C) T2-4 tumours. Original magnification:  20. (D) Western
blotting analysis of KRT7 protein expression in various biological samples from four individual bladder cancer patients. Protein extracts were obtained from
tumour tissue, plasma, urine supernatant, and urine pellet. Extracted protein of leucocytes obtained from a control person was used as a negative control
(neg. control). Expression of KRT7 transcript measured by microarray analysis shown in values relative to patient 1250-1.
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sbladder biopsies relating to both protein folding, mRNA splicing,
energy pathways, glucose catabolism, and lipid metabolism. A
neoplastic transformation of the urothelial cell-layer involves
increasing energy turnover; therefore, increased glucose catabolism
as well as lipid metabolism would be expected. Cells would also have
an increased demand of mRNA splicing capacity. Among the genes
distinguishing high-grade tumours from PUNLMP/low-grade tu-
mours, we found over-represented gene categories related mainly to
RNA processing and metabolism. Other categories were protein-
nucleus import, and regulation of cell cycle. In agreement with this,
cancer cells from high-grade tumours are distinguished from those
of PUNLMP/low-grade tumours by abnormal cell size, shape, large
hyperchromatic nuclei, and frequent mitoses.
When sorting the genes that were differentially expressed we
used two approaches, one was very conservative (Benjamini–
Hochberg correction for multiple comparisons) and was used for
changes from normal bladder to Ta tumours. Another approach
was used when looking at high-grade vs PUNLMP/low grades. This
was due to the fact that the fold changes between the grade groups
were lower, and a very conservative approach would remove all
genes from the listing. We therefore used the P-value without
correction for multiple comparisons, and named these ‘candidate
informative’ genes. The generated list of genes seems biologically
relevant (e.g. cell cycle, cell growth), and thus we believe that we
gained information that is useful, instead of simply discarding the
data. Of course, this means that such genes have to be proven by
other methods and in other studies. In this case we found a
separation into relevant subgroups using cluster analysis indicat-
ing robustness of the gene expression patterns within the groups.
The WHO/ISUP grading system (Epstein et al, 1998) is used to
divide Ta tumours into one of four subcategories; papilloma,
PUNLMP, low-grade, or high-grade. We performed an unsuper-
vised clustering analysis and demonstrated that we could obtain
grade-specific subgroups based on gene expression profiles. Two
distinct clusters (PUNLMP subcluster/high-grade subcluster) were
defined of both clinically and pathologically different tumours. We
found a statistically significant differential distribution of
PUNLMP and high-grade tumours to each of the two clusters.
We compared the median time to recurrence of the two subcluster
groups, and these were significantly different. The estimated
median relapse intervals were only 7 months for high-grade
subcluster tumours, and 63 months for PUNLMP subcluster
tumours. Thus, it was possible to separate clinical distinct groups
of Ta tumours on the basis of their gene expression pattern.
Cytokeratins belong to the intermediate filament family of
cytoplasmic proteins and is normally expressed by epithelial cells.
Cytoskeletal rearrangements seem to be an early change in the
neoplastic process of the urothelium (Southgate et al, 1999; Mor
et al, 2003; Sanchez-Carbayo et al, 2003). Consistent with the
literature, we found members of the cytokeration family, especially
KRT7, but also KRT8 highly expressed in Ta tumours (Southgate
et al, 1999; Mor et al, 2003). Several previous studies have examined
KRT7 expression in cancerous tissue of both primary and
metastatic origin (Bassily et al, 2000; Tot, 2000; Park et al, 2002).
Using comparison analysis, KRT7 was found as the most changed
transcript with an increased expression of 19.8-fold in Ta, and 8.5-
fold in T2-4 compared to normal bladder biopsies. Immuno-
histochemical stains for KRT7 showed cytoplasmic protein
expression specific for cancer cells in both Ta and T2-4 tumours,
but absent in stromal cells. Western blotting analysis using KRT7
specific antibody, consistently showed a high level of KRT7 protein
in Ta tumours and most T2-4 tumours compared to normal
bladder biopsies. Importantly, we did not find a KRT7 protein
overexpression in individual cancer cells (which are derived from
urothelial cells) compared to normal bladder cells. This suggests
that the KRT7 expression profile could correlate to the number of
cells expressing KRT7. Thus, the observed increase in KRT7 protein
(and mRNA) could reflect cancer cell enrichment in Ta tumour
biopsies, and might not only be a result of KRT7 overexpression. By
Western blotting analysis, we found a correlation between KRT7
protein and mRNA expression. This was in agreement with what we
showed previously for other keratins (Orntoft et al, 2002). We were
not able to detect KRT7 protein in either plasma or urine from
bladder cancer patients. In a few cases, we did detect KRT7 in urine
pellet samples from patients, but with low sensitivity. Even though
cancer cells in bladder tumours strongly expresses KRT7 protein, it
cannot be used as a new urine marker for bladder cancer within
this setup. However, an ELISA based method would be interesting
to use with its higher sensitivity and better quantitative properties.
Western blotting revealed the presence of at least three major
isoforms of the KRT7 polypeptide. One isoform with a molecular
weight similar to wild-type KRT7 (52kDa), and two additional
isoforms with molecular weights less than wild-type KRT7. As, it
was only possible to detect isoform b and c in cancerous tissue, we
speculate that these isoforms are cancer specific. Further studies are
needed to reveal the origin of the two alternative KRT7
polypeptides isoforms, they may be the result of either post-
translational modification or alternative splicing.
In conclusion, we have identified genes that alter expression in
early phases of bladder tumour formation, and characterised the
protein expression pattern of a number of those. We have identified
genes contributing to the molecular signature of high-grade
tumours, and shown, using clustering analysis, that primary Ta
tumours can be subdivided according to grade of atypia. In
addition, we have shown strong expression of both KRT7 transcript
and protein in bladder cancer, the presence of KRT7 protein in
urine pellets from bladder cancer patients, and the existence of
three major isoforms of this molecule, mainly in malignant cells.
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